CDK4 and pachyonychia congenita: The use of combination approaches is particularly important because resistance to CDK4/6 inhibitor monotherapy can develop in PC models, and data reveal that mTOR inhibitors are particularly effective at countering the acquisition of resistance and actively killing cells treated with CDK4/6 inhibitors.13,14